Autoimmune diseases in transplanted livers

Hiromi Ishibashi, Shinji Shimoda, Minoru Nakamura, M. Eric Gershwin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Liver transplantation (LT) is a standard therapeutic approach for the treatment of end-stage acute and chronic liver disease of various etiologies including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Results of LT for these autoimmune liver diseases are good, with a patient survival of 80 to 85% at 5 yr after LT. Transplant recipients, however, experience various complications, such as acute and chronic rejection, recurrence of disease, and chronic hepatitis. Recurrence of disease on the graft may be influenced by the genetic background of the recipient as well as other factors such as the degree of immunosuppression. Interestingly, autoimmunity and autoimmune disease can occur de novo following LT even for non-autoimmune liver diseases. However, the mechanisms that lead to autoimmunity or recurrence of autoimmune liver diseases after LT have not yet been defined. This chapter focuses on recurrence and occurrence of autoimmune diseases in transplanted livers.

Original languageEnglish
Title of host publicationLiver Immunology
Subtitle of host publicationPrinciples and Practice
PublisherHumana Press
Pages451-457
Number of pages7
ISBN (Print)9781588298188
DOIs
Publication statusPublished - Dec 1 2007

Fingerprint

Liver Transplantation
Autoimmune Diseases
Liver Diseases
Liver
Recurrence
Autoimmunity
Autoimmune Hepatitis
Sclerosing Cholangitis
Biliary Liver Cirrhosis
Chronic Hepatitis
Immunosuppression
Chronic Disease
Transplants
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Ishibashi, H., Shimoda, S., Nakamura, M., & Gershwin, M. E. (2007). Autoimmune diseases in transplanted livers. In Liver Immunology: Principles and Practice (pp. 451-457). Humana Press. https://doi.org/10.1007/978-1-59745-518-3_35

Autoimmune diseases in transplanted livers. / Ishibashi, Hiromi; Shimoda, Shinji; Nakamura, Minoru; Gershwin, M. Eric.

Liver Immunology: Principles and Practice. Humana Press, 2007. p. 451-457.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ishibashi, H, Shimoda, S, Nakamura, M & Gershwin, ME 2007, Autoimmune diseases in transplanted livers. in Liver Immunology: Principles and Practice. Humana Press, pp. 451-457. https://doi.org/10.1007/978-1-59745-518-3_35
Ishibashi H, Shimoda S, Nakamura M, Gershwin ME. Autoimmune diseases in transplanted livers. In Liver Immunology: Principles and Practice. Humana Press. 2007. p. 451-457 https://doi.org/10.1007/978-1-59745-518-3_35
Ishibashi, Hiromi ; Shimoda, Shinji ; Nakamura, Minoru ; Gershwin, M. Eric. / Autoimmune diseases in transplanted livers. Liver Immunology: Principles and Practice. Humana Press, 2007. pp. 451-457
@inbook{1c41181b6d6446359261b6b551404564,
title = "Autoimmune diseases in transplanted livers",
abstract = "Liver transplantation (LT) is a standard therapeutic approach for the treatment of end-stage acute and chronic liver disease of various etiologies including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Results of LT for these autoimmune liver diseases are good, with a patient survival of 80 to 85{\%} at 5 yr after LT. Transplant recipients, however, experience various complications, such as acute and chronic rejection, recurrence of disease, and chronic hepatitis. Recurrence of disease on the graft may be influenced by the genetic background of the recipient as well as other factors such as the degree of immunosuppression. Interestingly, autoimmunity and autoimmune disease can occur de novo following LT even for non-autoimmune liver diseases. However, the mechanisms that lead to autoimmunity or recurrence of autoimmune liver diseases after LT have not yet been defined. This chapter focuses on recurrence and occurrence of autoimmune diseases in transplanted livers.",
author = "Hiromi Ishibashi and Shinji Shimoda and Minoru Nakamura and Gershwin, {M. Eric}",
year = "2007",
month = "12",
day = "1",
doi = "10.1007/978-1-59745-518-3_35",
language = "English",
isbn = "9781588298188",
pages = "451--457",
booktitle = "Liver Immunology",
publisher = "Humana Press",
address = "United States",

}

TY - CHAP

T1 - Autoimmune diseases in transplanted livers

AU - Ishibashi, Hiromi

AU - Shimoda, Shinji

AU - Nakamura, Minoru

AU - Gershwin, M. Eric

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Liver transplantation (LT) is a standard therapeutic approach for the treatment of end-stage acute and chronic liver disease of various etiologies including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Results of LT for these autoimmune liver diseases are good, with a patient survival of 80 to 85% at 5 yr after LT. Transplant recipients, however, experience various complications, such as acute and chronic rejection, recurrence of disease, and chronic hepatitis. Recurrence of disease on the graft may be influenced by the genetic background of the recipient as well as other factors such as the degree of immunosuppression. Interestingly, autoimmunity and autoimmune disease can occur de novo following LT even for non-autoimmune liver diseases. However, the mechanisms that lead to autoimmunity or recurrence of autoimmune liver diseases after LT have not yet been defined. This chapter focuses on recurrence and occurrence of autoimmune diseases in transplanted livers.

AB - Liver transplantation (LT) is a standard therapeutic approach for the treatment of end-stage acute and chronic liver disease of various etiologies including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Results of LT for these autoimmune liver diseases are good, with a patient survival of 80 to 85% at 5 yr after LT. Transplant recipients, however, experience various complications, such as acute and chronic rejection, recurrence of disease, and chronic hepatitis. Recurrence of disease on the graft may be influenced by the genetic background of the recipient as well as other factors such as the degree of immunosuppression. Interestingly, autoimmunity and autoimmune disease can occur de novo following LT even for non-autoimmune liver diseases. However, the mechanisms that lead to autoimmunity or recurrence of autoimmune liver diseases after LT have not yet been defined. This chapter focuses on recurrence and occurrence of autoimmune diseases in transplanted livers.

UR - http://www.scopus.com/inward/record.url?scp=84889953926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889953926&partnerID=8YFLogxK

U2 - 10.1007/978-1-59745-518-3_35

DO - 10.1007/978-1-59745-518-3_35

M3 - Chapter

AN - SCOPUS:84889953926

SN - 9781588298188

SP - 451

EP - 457

BT - Liver Immunology

PB - Humana Press

ER -